Anti-viral Pharm for Hep B and C infx (Fitz) Flashcards

1
Q

list the biological agents used for tx of chronic hep B infx

A

IFN alpha-2b
PEG-IFN alpha-2b
PEGylated IFN alpha-2a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

list the nucleos(t)ide reverse transcriptase inhibitors used for tx of chronic hep B infx

A

Entecavir (guanosine)
Tenofovor (adenosine) for HBV and HIV
Lamivudine (cytosine) for HBV and HIV
Telbivudine (thymidine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

this class of hepatitis drugs are primarly used for tx of pts with well-compensated liver disease who do not wish to be on long-term tx or are planning to be pregnant within the next 2 or 3 years

A

IFN-alpha formulations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

list some cons for the use of IFN-a or PEG-IFN-a tx of chronic HBV infx:

A

DANGEROUS IN DECOMPENSATED CIRRHOSIS
parenteral
expensive
side effects such as flu-like syndrome, fever, myalgia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

the ISGF3:DNA complex upregulates this transcription factor through the use of IFN-a

A

IFN stimulated genes (ISG)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ISG degrades viral RNA through this MOA:

A

ISG –> 2’5’ OAS –> 2’5’-AAA activates Ribonuclease L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ISG inhibits protein synthesis through this MOA:

A

ISG –> PKR –> Phospho-eIF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

IFN-a (via IFN-y) favors this immune-mediated phenotype and ultimately leads to this negative effect:

A

cell-mediated Th1

increased inflammation and fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

aside from decompensated cirrhosis, what are some other adverse effects of IFN-a?

A

Flu-like syndrome after injection
fatigue and mental depression

Dose-limiting toxicity: BM suppression; Neurotoxicity-behavioral changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

when are nucleoside or nucleotide analog viral RT inhibitors with potent anti-HBV activity used?

A

for chronic, suppressive, oral single agent tx

These are much better tolerated than IFN-containing regimens but are NOT USUALLY CURATIVE.

CAN BE USED IN PTS WITH DECOMPENSATED OR COMPENSATED CIRRHOSIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the MOA of nucleos(t)ides?

A

inhibit viral RT/DNA polymerase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

NRTIs are pro-drugs that require conversion into their corresponding __, which are the ACTIVE anti-viral agents, in hepatocytes harboring HBV

A

nucleotide tri-phosphates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

list some HBV resistance mechanisms to nucleos(t)ides

A
  • impaired purine/pyrimidine kinase activity

- mutation of DNA polymerase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

this nucleotide analog is usueful in pts resistant to lamivudine, telbivudine, and entecavir

A

tenofovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

list the 1st line oral anti-HBV agents

A

tenofovir

entecavir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

list the 2nd line oral anti-HBV agents

A

lamivudine

telbivudine

17
Q

__ is a 1st line tx for wild-type HBV, and as an additional tx in pts with lamivudine, telbivudine, or entecavir resistance

A

tenofovir

resistant to tenofovir is rare

nephrotoxicity has been encountered at the dose used for HBV tx but occurs more often with higher doses used for HIV tx

18
Q

this 1st line oral anti-HBV agent has potent anti-viral activiy and a low rate of drug resistance. It may be Resistance to this drug occurs in ~50% of lamivudine-resistant pts after 5 yrs of tx. it may be a better option than adefovir or tenofovir in pts with renal insufficiency and in those who are at risk for renal insufficiency

19
Q

long-term efficacy of lamivudine is limited by ___

A

frequent emergence of drug-resistant HBV (YMDD –> YVDD mutant in catalytic domain of HBV polymerase) and subsequent virological breakthrough

20
Q

list the biological agents used to tx hep C infx

A

PEG-IFN a-2b

Pegylated IFN a-2a

21
Q

list a nucleoside used to tx hep C infx

22
Q

list direct acting anti-viral agents used to tx hep C infx

A

Simeprevir (NS3/4A protease)
Sofosbuvir (NS5B RNA dependent RNA polymerase)
Ledipasvir (NS5A)

23
Q

what is the HCV infx standard of care (through 2011)?

A

PEG-interferon PLUS ribavirin for 24-48 weeks

24
Q

Ribavirin-monophosphate has what anti-viral effect in hep C tx?

A

inhibits IMP dehydrogenase –> inhibits purine synthesis and salvage

25
Ribavirin-triphosphate has what anti-viral effect in hep C tx?
inhibits RNA-dependent RNA polymerase --> inhibits RNA replication
26
what is the immunomodulatory MOA of ribavirin?
potentiates IFN action. Alters the balance between proinflammatory (Th1 and Th2) cytokines
27
how is ribavirin metabolized? How is it cleared? where does it tend to get concentrated?
hepatic metabolism renal clearance (t1/2 ~1 day) 60x concentrated in erythrocytes (t1/2 ~40 days!!)
28
List contraindications of ribavirin:
- causes hemolytic anemia and is contraindicated in pts with anemia - Pregnancy category X. May cause birth defects and fetal death. Pts must have a negative pregancy test prior to therapy and have monthly pregnancy test during therapy and 6 months post therapy
29
direct-acting anti-viral agents interfere with HCV replication by inhibiting key viral enzymes such as __
NS3/4A serine protease, NS5B polymerase, and NS5A
30
simeprevir is a __ inhibitor
NS3/4A protease inhibitor
31
Ledipsasvir is a __ inhibitor
NS5A inhibitor
32
Sofosbuvir is a ___ inhibitor
NS5B polymerase inhibitor
33
__ block the NS3 catalytic site or the NS3/4A interaction
protease inhibitors
34
__ is a 2nd gen protease inhibitor. Used in combo with PEG-IFN and ribavirin or in combo with sofosbuvir +/- ribavrin for chronic genotype 1 infx
simeprevir
35
these inhibitors play a role in both viral replication and the assembly of the HCV
NS5A inhibitors
36
__ is a potent inhibitor of NS5A, effective across all genotypes, but with a low barrier to resistance. NS5A inhibitors significantly reduce HCV RNA levels when given with PEG-IFN and ribavirin
Ledipasvir
37
__ is the first NS5B inhibitor availabe in the US. It is used in combo with other anti-virals, including Ledipasvir
Sofosbuvir